FDA Advisory Committee to Review NPS Pharmaceuticals' Gattex New Drug Application

NPS Pharmaceuticals

today announced that NASDAQ has halted trading of the company's common stock. The U.S. Food and Drug Administration's (FDA) Gastrointestinal Drugs Advisory Committee is meeting today to review Gattex® (teduglutide), a novel, recombinant analog of human glucagon-like peptide 2 (a protein involved in the rehabilitation of the intestinal lining) being developed for the treatment of adults with short bowel syndrome. The Advisory Committee meeting is scheduled for 8:00 a.m. ET. The briefing materials can be found on the FDA website at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/ucm291609.htm. The Prescription Drug User Fee Act date for completion of